2021-004193-64: A Study to assess the effectivenss of Brilaroxazine (RP5063) in Subjects with an Acute Exacerbation of Schizophrenia. |
|
|
| Not yet recruiting | 3 | 402 | Europe | Brilaroxazine, RP5063, Tablet | Reviva Pharmaceuticals Holdings Inc., Reviva Pharmaceuticals Holdings Inc. | Acute Exacerbation of Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |